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Abstract
Background: Higher cardiorespiratory fitness (CRF) is associated with lower morbidity and mortality in patients with
coronary heart disease (CHD). The mechanisms for this are not fully understood. A more favourable cardiometabolic
risk factor profile may be responsible; however, few studies have comprehensively evaluated cardiometabolic risk
factors in relation to CRF amongst patients with CHD. We aimed to explore differences in cardiometabolic risk and
5-year all-cause mortality risk in patients with CHD who have low, moderate, and high levels of CRF.
Methods: Patients with CHD underwent maximal cardiopulmonary exercise testing, echocardiogram, carotid
intima-media thickness measurement, spirometry, and dual X-ray absorptiometry assessment. Full blood count,
biochemical lipid profiles, high-sensitivity (hs) C-reactive protein, and NT-proBNP were analysed. Patients were
defined as having low, moderate, or high CRF based on established prognostic thresholds.
Results: Seventy patients with CHD (age 63.1 ± 10.0 years, 86% male) were recruited. Patients with low CRF had a
lower ventilatory anaerobic threshold, peak oxygen pulse, post-exercise heart rate recovery, and poor ventilatory
efficiency. The low CRF group also had higher NT pro-BNP, hs-CRP, non-fasting glucose concentrations, and lower
haemoglobin and haematocrit. Five-year mortality risk (CALIBER risk score) was also greatest in the lowest CRF
group (14.9%).
Conclusions: Practitioners should interpret low CRF as an important clinical risk factor associated with adverse
cardiometabolic health and poor prognosis, study registry; www.researchregistry.com.
Keywords: Coronary Heart Disease, Cardiac Rehabilitation, Cardiometabolic Health, Exercise Training,
Atherosclerosis, VO2peak, Maximal Cardiopulmonary Exercise Testing, CALIBER 5-year risk
Key Points
1. Low cardiorespiratory fitness is associated with the
poorest cardiometabolic health in patients with
coronary heart disease.
2. Five-year risk of all-cause death and NT-proBNP
are highest amongst coronary heart disease patients
with the lowest cardiorespiratory fitness, even when
left ventricular ejection fraction is preserved.
Longer-term or higher intensity exercise-based car-
diac rehabilitation programmes that closely monitor
cardiovascular risk factors may be warranted for
coronary heart disease patients who have low car-
diorespiratory fitness.
Background
Cardiorespiratory fitness (CRF) or VO2peak predicts
all-cause and cardiovascular (CV) mortality in patients
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with coronary heart disease (CHD) [1–3]. We have
shown that in patients with CHD, low CRF confers the
highest mortality risk (54%) over a 14-year period when
compared to those categorised as having moderate (31%)
or high CRF [17%] [4]. Improvements in CRF resulting
from exercise-based cardiac rehabilitation (CR) may re-
duce mortality in patients who have low CRF [4–6].
Whilst higher CRF is a strong predictor of better sur-
vival outcomes, the mechanisms responsible for this asso-
ciation are not fully understood. Few studies have
comprehensively profiled the cardiometabolic health status
of patients with CHD in relation to established CRF cat-
egories. Higher all-cause mortality in patients with CHD
may not be entirely attributable to older age, cardiovascu-
lar disease (CVD) severity, and more comorbidities [7].
Unidentified and potentially treatable cardiometabolic risk
factors may cause the divergence in mortality rates ob-
served between patients with high and low CRF.
Biomarkers of cardiac dysfunction, inflammation, car-
diac autonomic function, arterial plaque status, renal
function, blood oxygen carrying capacity, and metabolic
control have received little attention in relation to CRF
in patients with CHD. Where limited data does exist,
CRF is often reported as estimated metabolic equiva-
lents (METS) from treadmill or cycle ergometer work-
loads [2, 4, 6]. Fitness estimation may be inaccurate in
patients with CHD, could result in individual patients
being inappropriately assigned to a specific CRF cat-
egory and, attenuate any prognostic signal [8]. The as-
sociation between cardiometabolic health and CRF
should be investigated using ‘gold-standard’ maximal
cardiopulmonary exercise testing (CPET).
This cross-sectional investigation aimed to assess dif-
ferences in CV and cardiometabolic health amongst pa-
tients with CHD when characterised as have low,
moderate, or high levels of CRF. We also investigated
differences in estimated 5-year risk of death using the
validated CALIBER composite scoring system [9].
Methods
Study Design
Data for this study were taken from the Cardiovascular
and cardiorespiratory Adaptations to Routine
Exercise-based Cardiac Rehabilitation study (CARE CR).
Ethical approval for the study was given by the Humber
Bridge NHS Research Ethics Committee-Yorkshire and
the Humber (12/YH/0278). The study is registered with
www.researchregistry.com (researchregistry3548). All
procedures were conducted in accordance with the eth-
ical standards outlined in the 1964 Helsinki declaration
and its later amendments.
The methodology for this study has been reported
elsewhere [10]. In brief, patients were recruited following
a recent hospital admission and referral to CR for stable
angina, myocardial infarction (MI), coronary artery by-
pass graft (CABG) surgery, or elective percutaneous cor-
onary intervention (PCI). After giving verbal consent,
patients were invited for assessment at Academic Cardi-
ology, Castle Hill Hospital, Kingston-Upon-Hull, United
Kingdom, where written informed consent was obtained.
Resting Haemodynamics, Anthropometry, and Body
Composition
Resting heart rate (HR) was determined at the end of
15 min, semi-supine rest using a 12-lead ECG (GE
Healthcare, Buckinghamshire, UK). Left arm brachial
blood pressure was recorded using an ECG-gated auto-
mated blood pressure (BP) cuff (Tango, SunTech
Medical, Eynsham, UK).
Stature (cm) was measured using a Leicester Height
Measure (SECA, Birmingham, UK) with patients stand-
ing, without footwear, in the Frankfort plane with their
heels and head positioned to the back of the stadi-
ometer. Waist circumference measurements were taken
1 cm above the iliac crest [11], and hip measurements
were taken from the widest aspect of the buttocks using
an inflexible tape measure. Both measurements were re-
corded in centimetre, and a ratio of the two was calcu-
lated to determine waist to hip circumference ratio [11].
Body composition was analysed using dual X-ray
absorptometry [DXA] (Lunar iDXA, GE Healthcare,
Buckinghamshire, UK). Total body mass (kg), lean body
mass (kg), total fat (%), android fat (%), and android
gynoid ratio were determined using the Lunar iDXA’s in-
tegrated software. DXA-derived total body mass was
used to determine body mass index (BMI; kg.m− 2).
Echocardiogram
Standard 2D, M-mode echocardiogram techniques were
used to determine left ventricular (LV) function. LV ejection
fraction (LVEF) was calculated using the Simpson’s method
from measurements of end-diastolic and end-systolic vol-
umes on apical 4-chamber and 2-chamber 2D views follow-
ing the guidelines of Schiller and colleagues [12]. LV systolic
dysfunction was diagnosed if LVEF was ≤ 45%.
Carotid Intima-Media Thickness and Carotid Plaque
Measurement
Carotid intima-media thickness (C-IMT) and carotid
plaque measurements were obtained using the Panaso-
nic CardioHealth Station (Panasonic Biomedical Sales
Europe BV, Leicestershire, UK) which has low measure-
ment variability [13, 14]. Measurements were taken
using previously outlined methods [10, 13] from a 1 cm
segment of the common carotid artery (CCA) located
1 cm proximally from the carotid bifurcation. Measure-
ments from the right and left CCA were taken in the
longitudinal plane at anterior (right CCA 150°; left CCA
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210°), lateral (right CCA 120°; 230°), and posterior (right
CCA 90°; left CCA 270°) angles, relative to ground. Each
C-IMT measurement was determined from the average
of 24 digital distance markers automatically placed be-
tween the intimal and medial boundaries and reported
to three decimal places. Carotid artery plaques were
measured in the longitudinal plane. The largest plaque
was taken as the representative measure of the patient’s
carotid plaque status and reported as being either <
1.0 mm, ≥ 1.0 to < 3.0 mm or ≥ 3.00 mm.
Blood Samples
Blood samples were taken from a vein at the antecubital
fossa and collected in ethylenediaminetetraacetic acid
(EDTA), potassium oxalate, and serum separating tubes
(SST). Full blood count, (haematocrit, haemoglobin, and
neutrophil and lymphocyte count) and estimated glom-
erular filtration rate (eGFR) were analysed on the day of
collection using a registered National Health Service
(NHS) pathology lab (Castle Hill Hospital, Hull, United
Kingdom). A further EDTA and potassium oxalate tube
were placed in a refrigerated (4 °C) centrifuge at
3000 rpm, for 15 min immediately after the blood draw.
Samples collected in SST tubes were allowed to clot for
30 min prior to being centrifuged under the same
conditions.
The ABX Pentra 400 biochemistry auto analyser
(Horiba, Montpellier, France) was used to analyse serum
triglycerides, total cholesterol, high-density lipoprotein
cholesterol (HDL), plasma glucose, and high-sensitivity
C-reactive protein (hs-CRP) in duplicate. Calibration
and quality controls were conducted in accordance with
manufacturer’s guidelines. Low-density lipoprotein
(LDL) was estimated using the Friedewald equation [15].
Cardiopulmonary Exercise Testing and Assessment of
Physical Activity
After 3 min of seated rest, CPET was conducted follow-
ing the modified Bruce treadmill protocol (GE Health-
care, Buckinghamshire, UK) [16] in accordance with
established guidelines [17–20]. A 12-lead ECG was mon-
itored continuously throughout the test. An ECG-gated
automated BP measurement was recorded at the start of
CPET and at the second minute of a test stage until the
end of the test. RPE scores were recorded at peak exer-
cise. HR was recorded at 1, 2, 3, and 6 min during the
passive seated recovery period.
Breath-by-breath gas exchange data were collected
using an Oxycon Pro metabolic cart (Jaeger,
Hoechburg, Germany). VO2peak was defined as the
mean VO2 (ml) over the last 30 s of the CPET.
VO2peak was adjusted for both body mass and lean
(DXA-derived) body mass (ml/kg/min). The ventila-
tory anaerobic threshold (VAT) was determined using
the V-slope method [21] by two independent investi-
gators. Where agreement on VAT scores was not
met, the results were discussed with a third inde-
pendent investigator and a consensus was reached.
The VAT was determined using the average of the
middle 5 of 7 consecutive breaths (excluding the
highest and lowest measures) and reported standar-
dised to patient body mass (ml/kg/min). The oxygen
uptake efficiency slope (OUES), VE/VCO2 slope, and
oxygen pulse (VO2/HR) were calculated as previously
described [19]. Self-reported weekly physical activity
levels were obtained by asking patients if they partic-
ipated in either 150 min of moderate physical activ-
ity, 75 min of vigorous physical activity, or both.
Determination of Cardiorespiratory Fitness Categories
Patients were categorised into three groups based on
their VO2peak. We converted VO2peak into metabolic
equivalents (METs) by dividing by 1 MET (estimated to
be equivalent to a VO2 of 3.5 ml/kg/min) to allow for
easier comparisons with other studies. Low CRF was de-
fined as a peak MET value of < 5 for men and < 4 for
women; high CRF was defined as peak MET > 7 for men
and > 6 for women. These thresholds were based on pre-
viously published prognostic thresholds [4–6, 22, 23].
Prognosis—CALIBER 5-year Risk Score
A 5-year risk of all-cause mortality was calculated for
each patient using the comprehensive online (www.cali-
berresearch.org/model) CALIBER 5-year risk score [9].
This model does not include any CRF measurements in
its calculation. A full list of included variables can be
found in Table 1. Five-year risk of all-cause mortality was
reported as a percentage to one decimal place.
Statistical Analysis
Statistical analysis was performed using SPSS version 22
(IBM, New York, USA). The Shapiro-Wilk test and his-
tograms were used to assess normality. Categorical data
are reported as percentages. Continuous normally dis-
tributed variables are displayed as mean with 95% confi-
dence intervals (95% CI) or standard deviation (±) where
specified. One-way analysis of variance (ANOVA),
one-way analysis of covariance (ANCOVA), and
chi-squared analysis were used to assess differences be-
tween CRF groups. The only covariate considered in
analysis was age as sex was used in assigning patients to
their CRF category.
Statistical significance was set at p < 0.05. Partial eta
squared (ηp
2) effect sizes were used to report the magni-
tude of group differences. Effect sizes of 0.01, 0.06, and
0.14 denoted small, moderate, and large effect sizes, re-
spectively [24]. Pearson correlations were used to assess
the strength of the relationship between CRF category
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and CALIBER 5-year risk of death. An r value of < 0.25,
0.26 to 0.50, 0.51 to 0.75, and, > 0.75 were considered




Seventy patients were recruited. Sixteen (23%) patients
had sustained an ST-elevation myocardial infarction
(STEMI), 22 (31%) had sustained a non-STEMI, and 19
(27%) had undergone elective PCI. Seven patients (10%)
were medically managed for stable angina, and six (9%)
had undergone CABG. The mean age of the cohort was
63.1 ± 10.0 years (BMI 29.2 kg.m− 2 ± 4.0; 86% male). The
mean LVEF was 55.0 ± 6.9%. The median time from car-
diac event to consent was 54 days (range 22 to 220). 94%
of patients were seen within 90 days.
Twenty-eight (40%), 32 (46%), and 10 (14%) of patients
were defined as having high, moderate, and low levels of
CRF, respectively. CRF group characteristics are shown
in Table 2. Patients with low CRF were older (p < 0.001)
and had a lower lean body mass than patients with
moderate (p = 0.029) and high CRF (p = 0.002). Com-
pared to patients with high (p < 0.001) and moderate
CRF (p = 0.002), patients with low CRF also had a lower
android gynoid ratio, higher resting HR (high CRF, p =
0.004; moderate CRF, p = 0.042), and a larger propor-
tion of patients suffering from type II diabetes (p =
0.028). Medications (Table 3) were comparable across all
three groups with the exception of diuretics which were
more commonly prescribed to patients in the low CRF
group (p = 0.001).
Cardiorespiratory Fitness and Physical Activity
Cardiorespiratory fitness and physical activity-related
variables are shown in Table 4. Differences in VO2peak
standardised to lean body mass, VAT, VO2/HR, and ex-
ercise test duration were observed across all groups.
Compared to patients with high CRF, VE/VCO2 slope
and OUES were both higher amongst patients in the
moderate and low CRF groups. Mean LVEF was not dif-
ferent across the groups and was not significantly corre-
lated with peak METs (r = 0.147; p = 0.224). One patient
in both the low and moderate CRF groups had a LVEF
< 40%. Compared to patients with high and moderate
CRF, patients with low CRF had the most impaired
1-min HR recovery, an indicator of cardiac autonomic
function. The proportion of patients who reported par-
ticipating in either 150 min of moderate (p = 0.011) or
75 min of vigorous physical activity per week was higher
in the high CRF group.
Blood Biomarkers and Cardiovascular Risk
Results of blood biochemical analyses are displayed in
Table 5. NT-proBNP was inversely associated with CRF
(r = -0.414) and was highest amongst patients with low
CRF. Four (40%) patients with low CRF had an
NT-proBNP > 400 pg/ml compared to eight (25%) and
one (4%) in the moderate and high CRF groups. One
patient in the low CRF group without previously diag-
nosed chronic heart failure (CHF) had an NT-proBNP
result > 2000 pg/ml with a mildly reduced LVEF (45%),
sinus rhythm, and with an eGFR of 73 mL/min/1.73 m2.
Lipid profiles did not differ between groups. Non-fasting
plasma glucose concentrations in the low CRF group
were higher than the moderate CRF group (p = 0.008).
hs-CRP was also highest in the low CRF group. Haem-
atocrit and haemoglobin differed between all groups.
Carotid Intima-Media Thickness
A moderate inverse correlation between left-sided
C-IMT measurements and CRF was observed (r = − 0.382;
p = 0.001) with larger measurements seen in the low
(0.926; 95% CI 0.797, 1.054; p = 0.002) and moderate CRF
groups (0.827; 95% CI 0.755, 0.898; p = 0.011) compared
to the high CRF group [0.689; 95% CI 0.612, 0.765] (Fig. 1).
There was no significant correlation between right sided
C-IMT and CRF (r = − 0.210; p = 0.080). The proportion
of patients with left-sided plaque score < 1 mm (Fig. 2) in-
creased with each CRF group (low 10%; moderate 25%;
high 39%). The proportion of patients exhibiting large
left-sided plaque scores (> 3 mm) decreased across
each group (low 40%; moderate 16%; high 4%; p =
Table 1 Variables Included in the CALIBER 5-Year Risk Score
Categorical Variables Continuous Variables
Sex Age (years)
Belongs to most deprived quintile Total cholesterol (mmol/L)
CAD diagnosis and severity HDL (mmol/L)
Interventions (last 6 months) Heart rate (beats per minute)
Smoking status Creatinine (micromol/L)












CAD coronary artery disease, BP blood pressure, COPD chronic obstructive
pulmonary disease, HDL high-density lipoprotein
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0.047). Patients with moderate and low CRF had in-
crementally higher proportions of patients with
right-sided plaque scores > 3 mm (moderate CRF
9.4%; low CRF 30%) compared to patients in the high
CRF who had no plaques > 3 mm (Fig. 2; p = 0.032).
All-Cause Mortality Estimation
Differences in CALIBER 5-year risk (Fig. 3) were ob-
served between all groups. Estimated risk was highest
in the low CRF group (14.9; 95% CI 11.4, 18.5%). The
moderate group had a 9.7% 5-year risk of death (95%
CI 7.7, 11.7%) whilst high CRF was associated with low-
est 5-year risk of death (3.7%; 95% CI 1.6, 5.8%). There
was a negative association between peak METS and
CALIBER 5-year risk score (r = − 0.538; r2 = 0.289; p =
< 0.001).
Statistical Adjustment for Age
Differences in left-sided mean C-IMT (p = 0.274;
ηp
2 = 0.039) became non-significant following age ad-
justment. Statistically significant differences for all
other variables remained unaltered after statistical ad-
justment for age.
Discussion
To our knowledge, this is the first study to comprehensively
profile the cardiometabolic and CV health status of patients
with CHD according to prognostically verified CRF categor-
ies [4–6, 22, 23]. Patients with the lowest CRF have the
poorest integrated cardiorespiratory function and cardio-
metabolic health. Patients with low CRF may also have im-
paired autonomic function and worse CV disease severity.
Low CRF was associated with the poorest CALIBER 5-year
all-cause mortality risk and ‘high risk’ status (defined as 3%
Table 2 Patient Characteristics Expressed as Mean (95% Confidence Intervals)
Variable High CRF, n = 28 Mod CRF, n = 32 Low CRF, n = 10 Partial eta squared p value
Sex (% male) 26 (93) 27 (84) 7 (70) 0.199
Age (years) 56.3 (53.1, 59.4)*✝ 67.2 (64.3, 70.2)✝ 69.3 (64.1, 74.5)* 0.326 < 0.001**
BMI (kg.m−2) 29.0 (27.5, 30.5) 28.9 (27.5, 30.3) 30.9 (28.3, 33.4) 0.030 0.363
Waist circumference (cm) 101.3 (97.3, 105.4) 102.6 (98.7, 106.4) 108.1 (101.4, 114.9) 0.043 0.235
Waist to hip ratio (cm) 0.96 (0.93, 0.98) 0.98 (0.95, 1.00) 0.96 (0.92, 1.01) 0.018 0.553
Android fat % 45.0 (42.0, 48.0) 48.0 (45.2, 50.8) 47.9 (42.9, 52.9) 0.034 0.316
Total fat % 35.9 (32.2, 39.6) 37.3 (33.8, 40.7) 41.1 (34.8, 47.3) 0.029 0.371
Lean body mass (Kg) 55.0 (51.9, 58.1)*✝ 50.2 (47.3, 53.1)✝ 45.3 (40.1, 50.5)* 0.145 0.005**
Android/gynoid ratio 1.31 (1.24, 1.38)* 1.26 (1.20, 1.32)x 1.06 (0.95, 1.17)*x 0.182 0.001**
LVEF (%) 56.6 (54.0, 59.2) 54.3 (51.8, 56.6) 52.8 (48.5, 57.1) 0.043 0.232
Resting HR (bpm) 56 (52, 69)* 59 (56, 63)x 67 (61, 74)*x 0.118 0.015**
Resting SBP (mmHg) 130 (122, 137) 124 (117, 131) 138 (125, 150) 0.056 0.147
Resting DBP (mmHg) 85 (80, 89) 82 (77, 86) 73 (65, 81) 0.083 0.055
FEV1/FVC ratio 0.78 (0.75, 0.81) 0.75 (0.72, 0.78) 0.75 (0.70, 0.80) 0.042 0.237
Presenting diagnosis
MI (%) 17 (61) 15 (47) 6 (60) 0.642
PCI (%) 8 (29) 11 (34) 1 (10)
Angina (%) 2 (7) 3 (9) 2 (20)
CABG (%) 1 (4) 3 (9) 1 (10)
Past medical history
Previous MI (%) 6 (21) 6 (19) 2 (20) 0.186
Type II diabetes (%) 3 (12) 6 (19) 5 (50) 0.028**
Atrial fibrillation (%) 0 (0) 2 (6) 1 (10) 0.269
Smoker (%) 1 (4) 1 (3) 2 (20) 0.238
Ex-smoker (%) 16 (57) 16 (50) 7 (70)
Mod moderate, BMI body mass index, LVEF left ventricular ejection fraction, HR heart rate, SBP systolic blood pressure, DBP diastolic blood pressure, FEV1/FVC ratio
of forced expiratory volume in 1 s to forced vital capacity, MI myocardial infarction, PCI percutaneous coronary intervention, CABG coronary artery bypass graft
**Significant group effect
*Significant difference between high CRF and low CRF
✝Significant difference between high CRF and moderate CRF
xSignificant difference between mod CRF and low CRF
Nichols et al. Sports Medicine - Open  (2018) 4:22 Page 5 of 11
Table 4 Cardiorespiratory Fitness and Physical Activity Characteristics Expressed as Mean (95% Confidence Intervals)
Variable High CRF, n = 28 Mod CRF, n = 32 Low CRF, n = 10 Partial eta squared
VO2peak (ml/kg/min) 28.5 (27.3, 29.7)
+ 20.7 (19.5, 21.8)+ 14.9 (12.8, 16.9)+ –
VO2peak (L/min) 2478.2 (2333.0, 2623.5)
+ 1749.0 (1613.1, 1884.9)+ 1273.8 (1030.7, 1516.8)+ –
VO2peak-lean (ml/kg/min) 45.2 (43.4, 47.0)
+ 34.8 (33.2, 36.5)+ 26.8 (23.8, 29.8)+ 0.670
VAT (ml/kg/min) 20.7 (19.3, 22.1)+ 14.6 (13.3, 15.9)+ 11.2 (8.9, 13.6)+ 0.494
VE/VCO2 slope 30.1 (28.2, 32.1)*
✝ 37.4 (35.6, 39.2)✝ 38.5 (35.2, 41.7)* 0.354
VO2/HR (ml/beat) 17.0 (15.8, 18.2)
+ 13.8 (12.7, 14.9)+ 11.3 (9.4, 13.3)+ 0.311
OUES 2718.3 (2555.3, 2881.3)*✝ 1963.5 (1811.1, 2116.0)✝ 1699.0 (1426.2, 1971.7)* 0.485
eBR (%) 30.3 (23.6, 36.9) 28.1 (22.0, 34.3) 37.0 (26.0, 48.1) 0.028
Peak HR (bpm) 147 (141, 153)*✝ 128 (122, 134)✝ 119 (108, 129)* 0.308
Peak RER 1.13 (1.09, 1.12)* 1.09 (1.05, 1.12)x 0.97 (0.91, 1.04)*x 0.181
Peak RPE 18 (17, 19) 18 (17, 19) 17 (15, 18) 0.072
1 min HR recovery (bpm) − 36 (− 32, − 40)* − 30 (− 26, − 34)x − 18 (− 11, −25)*x 0.209
2 min HR recovery (bpm) − 54 (− 50, − 59)+ − 45 (− 40, − 49)+ − 32 (− 25, −38)+ 0.312
3 min HR recovery (bpm) − 60 (− 56, − 65)+ − 49 (− 45, − 53)+ − 37 (− 30, −44)+ 0.359
6 min HR recovery (bpm) − 67 (− 62, − 71)+ − 54 (− 50, − 58)+ − 41 (− 33, − 48)+ 0.377
Exercise test duration (s) 963.2 (916.3, 1010.1)+ 747.8 (703.9, 791.6)+ 488.3 (409.8, 566.8)+ 0.635
METs 8.1 (7.8, 8.5)+ 5.9 (5.6, 6.2)+ 4.3 (3.7, 4.8)+ –
Maximal CPET (%) 26 (93) 26 (81) 6 (60) 0.058
Achieves 150 min of moderate activity per week (%) 18 (64)+ 9 (28) 5 (50) 0.011**
Achieves 75 min of vigorous activity per week (%) 7 (25)+ 1 (3) 0 (0) 0.013**
VO2peak peak oxygen uptake, VAT ventilatory anaerobic threshold, VE/VCO2 ventilatory efficiency with respect to CO2 elimination, VO2/HR oxygen pulse, OUES
oxygen uptake efficiency slope, eBR estimated breathing reserve, HR heart rate, bpm beats per minute, RER respiratory exchange ratio, RPE rating of perceived
exertion; S seconds, METs metabolic equivalents
**Significant group effect
*Significant difference between high CRF and low CRF
✝Significant difference between high CRF and moderate CRF
xSignificant difference between mod CRF and low CRF
+Significantly different from all other groups
Table 3 Number (%) of Medications Taken by Patients
Medication High CRF, n = 28 Mod CRF, n = 32 Low CRF, n = 10 p value
Aspirin (%) 27 (96) 31 (97) 10 (100) 0.838
Ticagrelor (%) 15 (54) 17 (53) 3 (30) 0.393
Clopidogrel (%) 10 (36) 8 (25) 3 (30) 0.665
Anti-coagulants (%) 0 (0) 1 (3) 1 (10) 0.263
Beta-blockers (%) 24 (86) 29 (91) 7 (70) 0.266
ACE-inhibitors (%) 19 (68) 16 (50) 7 (70) 0.291
Angiotensin receptor blockers (%) 0 (0) 5 (16) 1 (10) 0.096
Statins (%) 25 (89) 32 (100) 10 (100) 0.095
Diuretics (%) 1 (4) 1 (3) 5 (50) 0.001**
Calcium channel blockers (%) 4 (14) 8 (25) 4 (40) 0.502
Nitrates (%) 2 (7) 3 (9) 3 (30) 0.233
ACE angiotensin converting enzyme
**Significant group effect
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annual mortality risk [26]) despite the risk model not in-
cluding CRF-based measurements. The CALIBER model
includes an extensive set of all-cause mortality predictor
variables, including sociodemographics, CHD severity and
phenotype, primary CVD risk factors, CVD and non-CVD
comorbidities, psychosocial factors, and biomarkers. This
provides further evidence that CRF and other CPET-derived
variables should be treated as ‘clinical vital sign’ [27].
An important finding of this study was that
NT-proBNP levels and VE/VCO2 slopes were highest in
the moderate and low CRF groups. This suggests a
greater degree of cardiac dysfunction, ventilatory perfu-
sion mismatch, or heightened peripheral chemoreceptor
sensitivity as seen in patients with CHF [28, 29].
NT-proBNP levels and VE/VCO2 slopes were higher
even in the absence of significant resting LV impairment.
It is possible that patients with CHD and low CRF have
undiagnosed CHF or are in the early stages of its devel-
opment. Future research is required to determine
whether lower CRF in patients with CHD confers a
Fig. 1 Carotid intima-media thickness measurements in low, moderate, and high cardiorespiratory fitness groups. Mean left-sided carotid
intima-media thickness measurements (solid grey bars) were higher in the low and moderate cardiorespiratory fitness categories. Mean
right-sided carotid intima-media thickness (lines) did not differ between groups. Mod =moderate; CRF = cardiorespiratory fitness *Significant
difference between high CRF and low CRF; ✝Significant difference between high CRF and moderate CRF
Table 5 Blood Biomarkers Expressed as Mean (95% Confidence Intervals)
Variable High CRF, n = 28 Mod CRF, n = 32 Low CRF, n = 10 Partial eta squared p value
NT-proBNP (ng/L) 86.1 (11.4, 1428.0) *✝ 217.0 (33.9, 1916.0)✝ 464.0 (26.9, 2735.0)* - < 0.001**
Total Chol (mmol/L) 3.6 (3.2, 3.9) 3.7 (3.4, 4.0) 3.9 (3.3, 4.5) 0.017 0.579
LDL Chol (mmol/L) 1.7 (1.4, 1.9) 1.8 (1.6, 2.1) 1.9 (1.4, 2.3) 0.019 0.529
HDL Chol (mmol/L) 1.2 (1.0, 1.3) 1.2 (1.0, 1.3) 1.4 (1.2, 1.6) 0.052 0.176
TC/HDL ratio 3.2 (2.9, 3.5) 3.3 (3.0, 3.6) 3.0 (2.5, 3.6) 0.01 0.713
Triglycerides (mmol/L) 1.6 (1.3, 1.9) 1.5 (1.2, 1.8) 1.4 (0.9, 2.0 0.011 0.691
Glucose (mmol/L) 5.7 (3.3, 13.8) 5.2 (4.1, 22.2)x 6.4 (5.5, 16.9)x - 0.012**
hs-CRP (mg/L) 1.4 (0.3, 2.5)* 2.8 (1.7, 3.8) 4.2 (2.3, 6.2)* 0.099 0.033**
Neutrophil/lymphocyte ratio 2.4 (2.1, 2.8) 2.8 (2.4, 3.1) 3.3 (2.7, 3.8) 0.084 0.052
Haematocrit (%) 0.423 (0.410, 0.435)+ 0.405 (0.393, 0.417)+ 0.376 (.355, 0.397)+ 0.180 0.001**
Haemoglobin (g/L) 145.5 (140.7, 150.2)+ 138.2 (133.7, 142.6)+ 125.6 (117.6, 133.6)+ 0.219 < 0.001**
eGFR (mL/min/1.73 m2) 80.2 (75.2, 85.3) 76.2 (71.4, 80.9) 71.0 (62.6, 79.4) 0.053 0.160
NT-proBNP N-terminal prohormone brain natriuretic peptides, Chol cholesterol, LDL low-density lipoproteins, HDL high-density lipoproteins, hs-CRP high-sensitivity
C-reactive protein, eGF estimated glomerular filtration rate
**Significant group effect
*Significant difference between high CRF and low CRF
✝Significant difference between high CRF and moderate CRF
xSignificant difference between moderate CRF and low CRF
+Significantly different from all other groups
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greater risk of developing CHF. Closer monitoring for
signs and symptoms of CHF may be needed for patients
who enter CR and have low CRF.
The prognostic value of a high VE/VCO2 slope and/or
NT-proBNP has been well-described in CHF [30–32].
However, the value of VE/VCO2 slope and NT-proBNP
levels has also been shown in CHD. Elevated values
predict all-cause mortality [33], cardiovascular mortality
(~ 5 year follow-up), and the development of CHF and
stroke [34]. A high VE/VCO2 is independently associated
with high NT-proBNP levels, as well as ventricular re-
modelling [35]. Our findings suggest that patients with
both low and moderate CRF levels are at greatest risk of
having such adverse health outcomes, corroborated by
their higher CALIBER 5-year risk.
Traditional risk factors such as angina symptoms,
prior MI, atrial fibrillation, claudication, type II diabetes,
CHF, and smoking history do not entirely explain the in-
creased mortality risk associated with having low CRF.
Physical activity participation and higher CRF have been
established as important independent causative factors
for recurrent events [7]. In our study, patients defined as
having high CRF reported participating in regular phys-
ical activity and had the lowest 5-year risk of death. This
was accompanied by a lower resting HR and a quicker
post-exercise HR recovery, indicators of autonomic
function which also carry prognostic value. Interestingly
however, no differences were evident in standard an-
thropometric indices (BMI or waist circumference) or in
DXA-derived body fat content across the CRF groups.
The link between cardiometabolic profile, body
composition, and cardiovascular risk has been widely
reported and there is often an emphasis on reducing
overweight and obesity states in CR programmes. In
Fig. 3 CALIBER 5-year all-cause mortality risk scores were incrementally higher across the three cardiorespiratory fitness groups. Mod =moderate;
CRF = cardiorespiratory fitness+Significantly different from all other groups
Fig. 2 Left- and right-side common carotid artery plaque severity in patients with high, moderate, and low cardiorespiratory fitness. Black bars
indicate the proportion of patients with plaques < 1 mm and diagonal lines indicate the proportion of patients with plaques between 1 and
3 mm. Grey bars indicate the proportion of patients with plaques > 3 mm. Mod =moderate; CCA = common carotid artery
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our study, patients with higher CRF had a larger pro-
portion of lean tissue and more favourable abdominal
fat distribution. Low CRF was only associated with la-
tent changes in body composition. Changes were not
evident when assessing patients with routinely applied
anthropometric techniques, such as BMI and waist
circumference. Whilst overweight patients with CHD
have been reported to benefit from a better prognosis
than their leaner counterparts, [36], the association
between higher BMI and reduced all-cause mortality
may depend on a patients’ CRF. Those characterised
as having low CRF appear to benefit from improved
survival whilst fitter individuals do not [37, 38]. Our
findings (incorporating criterion fitness and ‘fatness’
measures) suggest that maintaining or improving CRF
may help lower recurrent cardiovascular risk in pa-
tients with CHD. However, our sample is relatively
small and only 10 patients were identified as having a
low CRF (n = 10). This may increase the likelihood of
statistical error (type I/type II error) when comparing
CRF groups. However, many of the effect sizes (ηp2)
associated with differences in cardiometabolic risk
were large. Furthermore, the 95% CI indicate distinct
values for many cardiometabolic variables across the
CRF groups. However, further research using a larger
patient cohort is required to confirm if our findings
are representative of the wider CHD population.
As reported by others [4, 6], our data shows that pa-
tients with high CRF have lower CALIBER 5-year risk
scores compared to patients with low and moderate CRF.
In previous studies [4, 6], patients characterised as having
high CRF were shown to have superior survival over a
15-year period. Barons and colleagues [6] reported that
within their low CRF group, a history of MI, PCI, and an-
gina were associated with the highest risk of death. Our
data do not confirm this. However, similar to our findings,
Taylor et al. [4] reported that prior MI is not more preva-
lent amongst patients with low CRF. It is possible that size
and location of MI are responsible for differences in car-
diac dysfunction and mortality risk.
Patients with a high CRF also had smaller left-sided
C-IMT measurements compared to patients with moder-
ate or low CRF. This may be because patients with a high
CRF also had a better cardiometabolic profile, including
high levels of self-reported physical activity. Exercise train-
ing can improve cardiovascular risk factor profiles in pa-
tients with CHD [39] and attenuate C-IMT and carotid
plaque progression in as little as 6 to 12 months [40, 41].
It is however important to acknowledge that older age
attenuated the relationship between C-IMTand CRF.
Conclusions
Identification of patients with low CRF and CHD appears
to be an effective means of identifying those at highest
cardiometabolic risk, and increased risk of 5-year all-cause
mortality. Exercise testing is widely applied in cardiological
and CR environments. Longer-term, or higher intensity
exercise-based CR programmes may help improve the car-
diometabolic health of patients with CHD and low CRF.
Abbreviations
± : Standard deviation; 95% CI : 95% confidence Intervals;
ANCOVA: Analysis of covariance; ANOVA: Analysis of variance; BMI: Body
mass index; BP: Blood pressure; CABG: Coronary artery bypass graft;
CCA: Common carotid artery; CHD: Coronary heart disease; CHF: Chronic
heart failure; C-IMT: Carotid intima-media thickness; CPET: Cardiopulmonary
exercise test; CR: Cardiac rehabilitation; CRF: Cardiorespiratory fitness;
CV: Cardiovascular; CVD: Cardiovascular disease; DXA: Dual X-ray absorpti-
ometry; ECG: Electrocardiogram; EDTA: Ethylenediaminetetraacetic acid; e-
GFR: Estimated glomerular filtration rate; Hb: Haemoglobin; Hct
: Haematocrit; HDL: High-density lipoproteins; HR: Heart rate; hs-CRP: High-
sensitivity C-reactive protein; LDL: Low-density lipoproteins; LV: Left
ventricular; LVEF: Left ventricular ejection fraction; METs: Metabolic
equivalents; MI: Myocardial infarction; NHS: National Health Service; NT-
proBNP: Terminal pro B type natriuretic peptide; VO2/HR: Oxygen pulse;
OUES: Oxygen uptake efficiency slope; PCI: Percutaneous coronary
intervention; RPE: Rating of perceived exertion; SST: Serum separating tube;
VAT: Ventilatory anaerobic threshold; VE/VCO2 slope: Ventilatory efficiency
with respect to CO2 elimination; VO2: Oxygen uptake; VO2peak: Peak oxygen
uptake; ηp2: Partial eta squared
Acknowledgements
We would like to thank Hull and East Riding Cardiac Trust Fund for providing
financial support enabling blood sample analysis. We would also like to
thank Wendy Summer, Lesley Richardson, and Emma Smith for their support
recruiting patients to this study.
Funding
Funding for blood sample analysis was provided by Hull and East Riding
Cardiac Trust Fund.
Availability of Data and Materials
The dataset supporting the conclusions of this article are available via
request to the corresponding author.
Authors’ Contributions
SN contributed to study design, study management, data collection, data
analysis, and manuscript preparation. CT, RP, AKB, and FN provided extensive
support during data collection and manuscript preparation. TG contributed
significantly to the study design, trial management, and manuscript
preparation. ALC contributed to the study design and provided critical
manuscript preparation as well as providing medical support to the study.
SC contributed to the study design and data analysis, and reviewed multiple
versions of the manuscript. LI contributed significantly to the study design
and preparation, managed the study, and contributed to the manuscript
preparation. All authors read and approved the final manuscript
Ethical Approval and Consent to Participate
Ethical approval for the study was given by the Humber Bridge NHS
Research Ethics Committee-Yorkshire and the Humber (12/YH/0278). After
giving verbal consent, patients were invited for assessment at Academic
Cardiology, Castle Hill Hospital, Kingston-Upon-Hull, where written informed
consent was obtained.
Competing Interests
Partial salary funding for SN was received by City Health Care Partnership CIC
(Hull, United Kingdom). The authors declare that they have no competing
interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Nichols et al. Sports Medicine - Open  (2018) 4:22 Page 9 of 11
Author details
1Centre for Sport and Exercise Science, Sheffield Hallam University, Collegiate
Hall, Collegiate Crescent, Sheffield S10 2BP, UK. 2Carnegie School of Sport,
Leeds Beckett University, Fairfax Hall, Headingley Campus, Leeds LS6 3QS,
UK. 3Sport Health and Exercise Science, Don Building, University of Hull,
Cottingham Road, Hull HU6 7RX, UK. 4Academic Cardiology, Castle Hill
Hospital, Castle Road, Cottingham HU16 5JQ, UK. 5City Health Care
Partnership CIC, East Riding Community Hospital, Swinemoore Lane, Beverley
HU17 0FA, UK.
Received: 12 January 2018 Accepted: 14 May 2018
References
1. Franklin BA, Lavie CJ, Squires RW, Milani RV. Exercise-based cardiac
rehabilitation and improvements in cardiorespiratory fitness: implications
regarding patient benefit. Mayo Clin Proc. 2013;88(5):431–7.
2. McAuley PA, Artero EG, Sui X, Lee D-C, Church TS, Lavie CJ, et al. The
obesity paradox, cardiorespiratory fitness, and coronary heart disease. Mayo
Clin Proc. 2012;87(5):443–51.
3. Keteyian SJ, Brawner CA, Savage PD, Ehrman JK, Schairer J, Divine G, et al.
Peak aerobic capacity predicts prognosis in patients with coronary heart
disease. Am Heart J. 2008;156(2):292–300.
4. Taylor C, Tsakirides C, Moxon J, Moxon J, Dudfield M, Witte KK, et al.
Submaximal fitness and mortality risk reduction in coronary heart disease: a
retrospective cohort study of community-based exercise rehabilitation. BMJ
Open. 2016;6(6):e011125.
5. Martin BJ, Arena R, Haykowsky M, Hauer T, Austford LD, Knudtson M, et al.
Cardiovascular fitness and mortality after contemporary cardiac
rehabilitation. Mayo Clin Proc. 2013;88(5):455–63.
6. Barons MJ, Turner S, Parsons N, Griffiths F, Bethell H, Weich S, et al. Fitness
predicts long-term survival after a cardiovascular event: a prospective
cohort study. BMJ Open. 2015;5:e007772. https://doi.org/10.1136/bmjopen-
2015-007772
7. Mandic S, Myers J, Oliveira RB, Abella J, Froelicher VF. Characterizing differences
in mortality at the low end of the fitness spectrum in individuals with
cardiovascular disease. Eur J Cardiovasc Prev Rehabil. 2010;17(3):289–95.
8. Nichols S, Gleadall-Sidall DO, Antony R, Clark AL, Cleland JGF, Carroll S, et al.
Estimated peak functional capacity; an accurate method for assessing
change in peak oxygen consumption after cardiac rehabilitation? Clin
Physiol Funct Imaging. 2017; Ahead of print
9. Rapsomaniki E, Shah A, Perel P, Denaxas S, George J, Nicholas O, et al.
Prognostic models for stable coronary artery disease based on electronic
health record cohort of 102 023 patients. Eur Heart J. 2014;35(13):844–52.
10. Nichols S, Nation F, Goodman T, Clark AL, Carroll S, Ingle L. CARE CR-
cardiovascular and cardiorespiratory adaptations to routine exercise-based
cardiac rehabilitation: a study protocol for a community-based controlled
study with criterion methods. BMJ Open.2018;8:e019216. https://doi.org/10.
1136/bmjopen-2017-019216.
11. ACSM. ACSM’s guidelines for exercise testing and prescription. 10th ed.
Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins Health; 2017.
12. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H,
et al. Recommendations for quantitation of the left ventricle by two-
dimensional echocardiography. American Society of Echocardiography
Committee on standards, subcommittee on quantitation of two-
dimensional echocardiograms. J Am Soc Echocardiogr. 1989;2(5):358–67.
13. Nichols S, Milner M, Meijer R, Carroll S. Ingle L. Clinical Physiology and
Functional Imaging: Variability of automated carotid intima-media thickness
measurements by novice operators; 2014.
14. Vanoli D, Wiklund U, Lindqvist P, Henein M, Näslund U. Successful novice’s training
in obtaining accurate assessment of carotid IMT using an automated ultrasound
system. European Heart Journal – Cardiovascular Imaging. 2013;15(6):637–42.
15. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of
low-density lipoprotein cholesterol in plasma, without use of the
preparative ultracentrifuge. Clin Chem. 1972;18(6):499–502.
16. Bruce RA, Kusumi F, Hosmer D. Maximal oxygen intake and nomographic
assessment of functional aerobic impairment in cardiovascular disease. Am
Heart J. 1973;85(4):546–62.
17. American Thoracic Society/American College of Chest Physicians. ATS/ACCP
statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med.
2003;167(2):211.
18. Taylor C, Nichols S, Ingle L. A clinician’s guide to cardiopulmonary exercise
testing 1: an introduction. Br J Hosp Med. 2015;76(4):192–5.
19. Nichols S, Taylor C, Ingle L. A clinician's guide to cardiopulmonary exercise
testing 2: test interpretation. Br J Hosp Med. 2015;76(5):281–9.
20. Balady GJ, Arena R, Sietsema K, Myers J, Coke L, Fletcher GF, et al. Clinician’s
guide to cardiopulmonary exercise testing in adults: a scientific statement
from the American Heart Association. Circulation. 2010;122(2):191–225.
21. Beaver WL, Wasserman K, Whipp BJ. A new method for detecting anaerobic
threshold by gas exchange. J Appl Physiol. 1986;60(6):2020–7.
22. Kavanagh T, Mertens DJ, Hamm LF, Beyene J, Kennedy J, Corey P, et al. Peak
oxygen intake and cardiac mortality in women referred for cardiac
rehabilitation. J Am Coll Cardiol. 2003;42(12):2139–43.
23. Myers J, Prakash M, Froelicher V, Do D, Partington S, Atwood JE. Exercise
capacity and mortality among men referred for exercise testing. N Engl J
Med. 2002;346(11):793–801.
24. Richardson JTE. Eta squared and partial eta squared as measures of
effect size in educational research. Educational Research Review. 2011;
6(2):135–47.
25. Berg KE, Latin RW. Essentials of research methods in health, physical education,
exercise science, and recreation: Lippincott Williams & Wilkins; 2008.
26. Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, et al.
2013 ESC guidelines on the management of stable coronary artery disease.
The task force on the management of stable coronary artery disease of the
European Society of Cardiology. Eur Heart J. 2013;34(38):2949–3003.
27. Ross R, Blair SN, Arena R, Church TS, Després J-P, Franklin BA, et al.
Importance of assessing cardiorespiratory fitness in clinical practice: a case
for fitness as a clinical vital sign: a scientific statement from the American
Heart Association. Circulation. 2016:65. CIR. 0000000000000461
28. Poole DC, Hirai DM, Copp SW, Musch TI. Muscle oxygen transport and
utilization in heart failure: implications for exercise (in) tolerance. Am J Phys
Heart Circ Phys. 2012;302(5):H1050–H63.
29. Clark AL, Poole-Wilson PA, Coats AJS. Exercise limitation in chronic heart
failure: central role of the periphery. J Am Coll Cardiol. 1996;28(5):1092–102.
30. Ingle L, Goode K, Carroll S, Sloan R, Boyes C, Cleland JGF, et al.
Prognostic value of the VE/VCO2 slope calculated from different time
intervals in patients with suspected heart failure. Int J Cardiol. 2007;
118(3):350–5.
31. Arena R, Myers J, Aslam SS, Varughese EB, Peberdy MA. Peak VO2 and VE/
VCO2 slope in patients with heart failure: a prognostic comparison. Am
Heart J. 2004;147(2):354–60.
32. Hartmann F, Packer M, Coats AJ, Fowler MB, Krum H, Mohacsi P, et al. NT-
proBNP in severe chronic heart failure: rationale, design and preliminary
results of the COPERNICUS NT-proBNP substudy. Eur J Heart Fail. 2004;6(3):
343–50.
33. Coeckelberghs E, Buys R, Goetschalckx K, Cornelissen VA, Vanhees L. Prognostic
value of the oxygen uptake efficiency slope and other exercise variables in
patients with coronary artery disease. Eur J Prev Cardiol. 2016;23(3):237–44.
34. Omland T, Sabatine MS, Jablonski KA, Rice MM, Hsia J, Wergeland R, et
al. Prognostic value of B-type natriuretic peptides in patients with
stable coronary artery disease: the PEACE trial. J Am Coll Cardiol. 2007;
50(3):205–14.
35. Van de Veire NR, Van Laethem C, Philippé J, De Winter O, De Backer G,
Vanderheyden M, et al. VE/Vco2 slope and oxygen uptake efficiency slope
in patients with coronary artery disease and intermediate peakVo2. Eur J
Cardiovasc Prev Rehabil. 2006;13(6):916–23.
36. De Schutter A, Lavie CJ, Patel DA, Artham SM, Milani RV. Relation of body
fat categories by Gallagher classification and by continuous variables to
mortality in patients with coronary heart disease. Am J Cardiol. 2013;111(5):
657–60.
37. Lavie CJ, McAuley PA, Church TS, Milani RV, Blair SN. Obesity and
cardiovascular diseases: implications regarding fitness, fatness, and severity
in the obesity paradox. J Am Coll Cardiol. 2014;63(14):1345–54.
38. Goel K, Thomas RJ, Squires RW, Coutinho T, Trejo-Gutierrez JF, Somers VK,
et al. Combined effect of cardiorespiratory fitness and adiposity on
mortality in patients with coronary artery disease. Am Heart J. 2011;161(3):
590–7.
39. Seki E, Watanabe Y, Shimada K, Sunayama S, Onishi T, Kawakami K, et al.
Effects of a phase III cardiac rehabilitation program on physical status and
lipid profiles in elderly patients with coronary artery disease: Juntendo
Cardiac Rehabilitation Program (J-CARP). Circulation journal : official journal
of the Japanese Circulation Society. 2008;72(8):1230–4.
Nichols et al. Sports Medicine - Open  (2018) 4:22 Page 10 of 11
40. Sato S, Makita S, Uchida R, Ishihara S, Majima M. Physical activity and
progression of carotid intima-media thickness in patients with coronary
heart disease. J Cardiol. 2008;51(3):157–62.
41. Byrkjeland R, Stensaeth KH, Anderssen S, Njerve IU, Arnesen H, Seljeflot I,
et al. Effects of exercise training on carotid intima-media thickness in
patients with type 2 diabetes and coronary artery disease. Influence of
carotid plaques Cardiovasc Diabetol. 2016;15:13.
Nichols et al. Sports Medicine - Open  (2018) 4:22 Page 11 of 11
